Efficient Induction of Th1-type Immune Responses to Hepatitis B Virus Antigens by DNA Prime-Adenovirus Boost
Immune Network
;
: 1-10, 2005.
Article
in English
| WPRIM
| ID: wpr-127006
ABSTRACT
BACKGROUND:
Chronic infection with hepatitis B virus (HBV) affects about 350 million people worldwide, which have a high risk of development of cirrhosis and hepatocellular carcinoma. Treatment of chronic HBV infection relies on IFN-alpha or lamivudine. However, interferon-alpha is effective in only about 30% of patients. Also, the occurrence of escape mutations limits the usage of lamivudine. Therefore, the development and evaluation of new compounds or approaches are urgent.METHODS:
We comparatively evaluated DNA and adenoviral vaccines expressing HBV antigens, either alone or in combined regimens, for their ability to elicit Th1-type immune responses in Balb/c mice which are believed to be suited to resolve HBV infection. The vaccines were tested with or without a genetically engineered IL-12 (mIL-12 N220L) which was shown to enhance sustained Th1-type immune responses in HCV E2 DNA vaccine.RESULTS:
Considering the Th1-type cytokine secretion and the IgG2a titers, the strongest Th1-type immune response was elicited by the DNA prime-adenovirus boost regimen in the presence of mIL-12 N220L. In addition, the codelivery of mIL-12 N220L modulated differentially the immune responses by different vaccination regimens.CONCLUSION:
Our results suggest that the DNA prime-adenovirus boost regimen in the presence of mIL-12 N220L may be the best candidate for HBV vaccine therapy of the regimens tested in this study and will be worthwhile being evaluated in chronic HBV patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
United Nations
/
Fibrosis
/
DNA
/
Immunoglobulin G
/
Vaccines
/
Hepatitis B virus
/
Immunotherapy, Active
/
Vaccination
/
Interferon-alpha
/
Carcinoma, Hepatocellular
Limits:
Animals
/
Humans
Language:
English
Journal:
Immune Network
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS